Trial Profile

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dazukibart (Primary)
Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
Focus Therapeutic Use
Sponsors Pfizer

21 Aug 2023 Status changed from not yet recruiting to recruiting.
11 Jul 2023 Planned initiation date changed from 21 Jun 2023 to 14 Jul 2023.
21 Jun 2023 Planned initiation date changed from 12 Jun 2023 to 21 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com